Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
AI Image

Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues

STAT • • business

Key Points:

  • Seawolf Therapeutics has raised $100 million from Versant Ventures, Eli Lilly, and other investors to develop non-viral gene delivery methods.
  • The startup aims to overcome challenges associated with viral gene therapy, such as immune responses and dosing limitations.
  • Sanofi has entered into a partnership with Seawolf Therapeutics, supporting its innovative approach.
  • Current viral gene therapies are effective but limited by single-dose administration and potential serious side effects at high doses.

Trending Business

Trending Technology

Trending Health